CEO Update | 8 August 2022

UK sector news to celebrate

Summertime can be a quiet time but there has been a string of high-profile announcements within the UK sector to celebrate.

Last week, RoslinCT announced that they have signed a business combination agreement with US advanced therapy CDMO Lykan Biosciences to form a global leading innovative advanced therapies CDMO. MiroBio, a company spun out of the University of Oxford and backed by Oxford Science Enterprises which focuses on antibodies, was acquired by Gilead for $405 million. Further good news in the antibody space as Apollo Therapeutics signed an exclusive license agreement with Avalo Therapeutics granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007 (camoteskimab).

Engaging with the Labour Party

While all eyes may be on who’ll be the next Conservative leader and Prime Minister, our experience from the recent BIA Parliament Day suggests that the Labour Party is busy developing its policies ready for a general election. This includes a review launched by the Shadow Chancellor, Rachel Reeves MP, looking at the environment for start-ups in the UK. We have submitted detailed evidence on the fragile state of financing for innovative young companies, difficulties with technology transfer and the importance of R&D tax credits, among other things. We have made a set of recommendations that the next Labour Government could take forward to support start-ups and continue the growth of our sector.

I am looking forward to a busy autumn engaging with decision-makers in both parties, starting with the Labour Party conference in September.  

Biomedical Catalyst Round 2

Next week, Round 2 of the Biomedical Catalyst (BMC) for Industry-led R&D is opening up for the UK registered SMEs, this stream of the BMC supports pre-market R&D projects. Innovate UK will invest up to £25 million to develop innovative solutions to address health or healthcare challenges. BIA was instrumental in securing the launch of the BMC in 2011/12 and we have made its continuation a key campaign focus. We conducted an analysis that demonstrated the economic and scientific impacts of the scheme.

I am taking a summer holiday for the next two weeks, so the excellent BIA team will ensure you are up to date with the latest in the next fortnight, and I’ll return to CEO blog duties in the first week of September when we will know who the new Prime Minister will be.

Steve circle.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates

CEO Update | 3 October 2022

We’ve moved out of our offices to enable the demolition of the Southside building in Victoria street. We are currently in interim offices and our new address is BioIndustry Association, LABs, Victoria House, Bloomsbury Way, London, WC1B 4DA. We say goodbye to Southside after over 11 years... Read on for an update on the Conservative Party and Labour Party conferences, Board Elections and TechBio UK Conference.

Member Spotlight: Interview with Moderna

Following the announcement about the BioIndustry Association (BIA) reaching a new milestone of 500 member companies earlier this week, we spoke with Darius Hughes, UK General Manager at Moderna to learn more about the mRNA global player and his intentions behind joining the trade association’s membership.

BIA celebrates breaking 500 members after Moderna enters membership

The BioIndustry Association (BIA) today has announced that its membership has passed 500 companies, as mRNA global player Moderna entered into the trade association’s membership.

CEO Update | 26 September 2022

Chancellor highlights the globally leading role of the life science sector in Friday’s mini-budget and launches a new UK TIBI-like investment initiative for innovative firm financing and sad news about former BIA CEO Aisling Burnand. Read on for updates on the party conferences, BIA events, Annual General Meeting and Board Elections plus our new office location.

More within